

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

CHECKLIST OF RESPONSIBILITIES FOR SCIENTIFIC EDITORS

Manuscript page number (Without Figures): 20	Rate: 6.2 CNY per page
	Editing Fee: 124 CNY
Figure count:0Figure handling time:0	min Rate: 1 CNY per min
	Editing Fee: 0 CNY
XML and PDF converting time: 60	min Rate: 1 CNY per min
	Editing Fee: 60 CNY
Manuscrip	t word count: 4659
Tota	al Editing Fee: <u>184 </u>
s	cientific Editor: <u>Jing-Jie Wang</u>

Date of signature: ______(month/day/year)

		Comments
Item No.	Specific items for verification	Yes=[Y]
		No= [N]
	General Information of the Manuscript	
	Name of journal: World Journal of Orthopedics	
	Manuscript NO.: 85660	
	Column: Retrospective Study	
	Title: Safety and outcomes of hip and knee replacement surgery in	
1	liver transplant recipients	[Y]
	Authors: Mohamed Ahmed, Abdelrhman Abumoawad, Fouad	
	Jaber, Hebatullah Elsafy, Saqr Alsakarneh, Laith Al Momani, Alisa	
	Likhitsup and John H Helzberg	
	Reviewer code: 03034605, and 04382733	
	First decision: 2023-08-14 23:13	



2

Baishideng Publishing

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com

https://www.wjgnet.com

Editorial Office's Comments

Science Editor: I recommend transfer to World Journal of World Journal of Orthopedics. I have reviewed the Peer-Review Report and the full text of the manuscript, all of which have met the basic publishing requirements of the World Journal of Orthopedics, and the manuscript is conditionally accepted. I have sent the manuscript to the author(s) for its revision according to the Peer-Review Report, Editorial Office's comments and the Criteria for Manuscript Revision by Authors. Before final acceptance, when revising the manuscript, the author must supplement and improve the highlights of the latest cutting-edge research results, thereby further improving the content of the manuscript. To this end, authors are advised to apply a new tool, the Reference Citation Analysis (RCA). RCA is an artificial intelligence technology-based open multidisciplinary citation analysis database. In it, upon obtaining search results from the keywords entered by the author, "Impact Index Per Article" under "Ranked by" should be selected to find the latest highlight articles, which can then be used to further improve an article under preparation/peer-review/revision. Please visit our **RCA** database for more information https://www.referencecitationanalysis.com/. Uniform presentation should be used for figures showing the same or similar contents; for example, "Figure 1Pathological changes of atrophic gastritis after treatment. A: ...; B: ...; C: ...; D: ...; E: ...; F: ...; G: ...". Please provide decomposable Figures (in which all components are

[Y]



Baishideng **Publishing**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com

https://www.wjgnet.com

movable and editable), organize them into a single PowerPoint file. Please check and confirm whether the figures are original (i.e. generated de novo by the author(s) for this paper). If the picture is 'original', the author needs to add the following copyright information to the bottom right-hand side of the picture in

PowerPoint (PPT): Copyright ©The Author(s) 2023.

Company Editor-in-Chief: I recommend transfer to World Journal of World Journal of Orthopedics. I have reviewed the Peer-Review Report and the full text of the manuscript, all of which have met the basic publishing requirements of the World Journal of Orthopedics, and the manuscript is conditionally accepted. I have sent the manuscript to the author(s) for its revision according to the Peer-Review Report, Editorial Office's comments and the Criteria for Manuscript Revision by Authors. Before final acceptance, when revising the manuscript, the author must supplement and improve the highlights of the latest cutting-edge research results, thereby further improving the content of the manuscript. To this end, authors are advised to apply a new tool, the Reference Citation Analysis (RCA). RCA is an artificial intelligence technology-based open multidisciplinary citation analysis database. In it, upon obtaining search results from the keywords entered by the author, "Impact Index Per Article" under "Ranked by" should be selected to find the latest highlight articles, which can then be used to further improve an article under preparation/peer-review/revision. Please visit **RCA** database for information 011r more



Telephone: +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com

https://www.wjgnet.com

	at: https://www.referencecitationanalysis.com/. Uniform	
	presentation should be used for figures showing the same or similar	
	contents; for example, "Figure 1Pathological changes of atrophic	
	gastritis after treatment. A:; B:; C:; D:; E:; F:; G:".	
	Please provide decomposable Figures (in which all components are	
	movable and editable), organize them into a single PowerPoint file.	
	Please check and confirm whether the figures are original (i.e.	
	generated de novo by the author(s) for this paper). If the picture is	
	'original', the author needs to add the following copyright	
	information to the bottom right-hand side of the picture in	
	PowerPoint (PPT): Copyright ©The Author(s) 2023.	
3	The fixed headings are copied.	[Y]
	The title concisely summarizes the main topic of the study and is	
	not too long (no more than 18 words). Words such as 'exploration',	
4	'research', 'analysis', 'observation', and 'investigation' are avoided.	[Y]
	The title does not start with 'The' and does not include any Arabic	
	numbers or uncommon abbreviations.	
5	A short running title is provided (no more than 6 words).	[Y]
	The authors' full family (sur)names and full/abbreviated first	
6	names are listed on the title page and are consistent with those	[Y]
	listed in the signed BPG Copyright License Agreement form.	
	The 'Author contributions' passage describes the specific	
	contribution(s) made by each author. The author's names are listed	
	in the following format: full family (sur)name followed by	
7	abbreviated first and middles names.	[Y]
	e.g., "Wang CL and Liang L contributed equally to this work; Wang	
	CL, Liang L, Fu JF, Zou CC, Hong F and Wu XM designed the	
	research study; Wang CL, Zou CC, Hong F and Wu XM performed	



	the research; Xue JZ and Lu JR contributed new reagents and analytic tools; Wang CL, Liang L and Fu JF analyzed the data; and Wang CL, Liang L and Fu JF wrote the manuscript. All authors have read and approve the final manuscript."	
8	The 'Supported by' statement describes the source(s) of financial support and includes the corresponding identification number(s) and program ID(s) if available, and contains no spelling errors.	[N]
9	The 'Corresponding author' passage provides the corresponding author's full first and family (sur)names, abbreviated title (e.g., MD, PhD), affiliated institute's name and complete postal address (including zip code) and e-mail (written in all lowercase), and contains no spelling errors.	[Y]
10	The Manuscript Tracking information (<i>i.e.</i> , Received, Peer review started, First decision, Revised, Accepted, Article in press, and Published online) are provided along with the corresponding editor and date for each item, and contain no spelling errors.	[Y]
11	The Abstract section is formatted according to the article-specific style (structured vs unstructured) and word count thresholds, as follows: Commentary, Frontier, Diagnostic Advances, Medical Ethics, Minireview, Review, Therapeutics Advances, and Topic Highlight: Non-structured abstract that is no less than 200 words. Field of Vision, Case Report and Letter to the Editor: Non-structured abstract that is no less than 150 words. Research articles: Structured abstract with subsections for AIM (no more than 20 words); METHODS (no less than 80 words); RESULTS (no less than 120 words); and CONCLUSION (no more than 26	[Y]



	words).	
	The 'Key words' list provides 5-10 keywords that reflect the main	
12	content of the study. The first letter of each keyword is capitalized,	[Y]
	and each keyword is separated by a semicolon.	
	The "citation" contains authors' names and manuscript title. The	
	name of the first author should be typed in bold letters; the family	
	(sur) name of all authors should be typed with the first letter	
	capitalized, followed by their abbreviated first and middle initials.	
13	For example, an article by Jae Moon Yoon, Ki Young Son, Chun Sick	[Y]
	Eom, Daniel Durrance, Sang Min Park will be written as Yoon JM,	
	Son KY, Eom CS, Durrance D, Park SM. Pre-existing diabetes	
	mellitus increases the risk of gastric cancer: A meta-analysis. World J	
	Gastroenterol 2019; In press	
14	The 'Core tip' provides a summary (less than 100 words) of the	[Y]
	study that outlines the most innovative and important arguments	
	and core contents of the paper and will serve to effectively attract	
	readers.	
	The 'INTRODUCTION' section clearly describes the relevant	
	background information for the study. Only the most relevant and	
	current (within the past 5 years) literature is cited, with the	
	exception of rare instances of seminal literature citations. All	[Y]
	technical terms and/or abbreviations are explained and/or defined,	
45	with the full name of abbreviations given upon first appearance in	
15	the text and the abbreviation presented in parentheses [i.e.,	
	"computed tomography (CT)"]. First-person pronouns (e.g., 'I',	
	'we') are used appropriately to clearly indicate the work performed	
	by the author(s). When weaknesses of previous studies are	
	described in the text to highlight the innovations related to the	
	current study, the information is presented carefully.	



Г		
	The 'MATERIALS AND METHODS' section clearly and accurately	
16	describes all materials and methods used to obtain the data	[V]
	presented in the article and is adequate for a reader to repeat the	[Y]
	study.	
	The 'RESULTS' section concisely describes the observational and	
	experimental results. Representative data and data that have	
17	scientific significance are emphasized. Data is presented in either	
	the text, a table or figure (i.e., chart, diagram, graph or image), but is	[Y]
	not repeated among each. Information presented in the tables and	
	figures clearly describes the trends, meaning, and inferences.	
	Results described in textual form are accurate, concise and clear.	
	Statistical symbols are accurate. Statistical significance is expressed	
18	as ${}^{a}P$ < 0.05, ${}^{b}P$ < 0.01 (P > 0.05 usually does not need to be denoted).	
	If there are other series of <i>P</i> values, cP < 0.05 and dP < 0.01 are used,	[Y]
	and a third series of <i>P</i> values is expressed as $^{\rm e}P$ < 0.05 and $^{\rm f}P$ < 0.01.	
	Statistical data is expressed as mean \pm SD or mean \pm SE.	
	The 'DISCUSSION' section (1) describes the main purpose and	
19	hypothesis of the study; (2) summarizes the most important results;	
	(3) illustrates and explains the results (but does not simply repeat	[Y]
	the data) and draws conclusions or inferences based on the results;	
	(4) points out the limitations of the study and their impact on the	
	results, as well as proposes further advice on future research	
	topic(s) or direction(s); and (5) describes the theoretical significance	
	and practical value of the findings.	
	The 'ACKNOWLEDGEMENTS' section expresses gratitude to any	
20	individuals or organizations for technical support (i.e., providing	
	instrumentation, equipment or experimental materials, and/or	[N]
	assistance in experimental work), non-technical services (i.e., useful	
	inspiration, suggestions, guidance, or review), and/or any other	
	auxiliary work.	
L	1	



The 'ARTICLE HIGHLIGHTS' section provides comments for original articles in accordance with the specified format. The 'REFERENCES' section lists the references in the Vancouver style. This style uses Arabic numeral in-text citations based on the order of the first appearance of a source in the text. For citations where the author's name is indicated in the text, a superscript number should be placed following the name (<i>i.e.</i> , "Pang <i>et al</i> "). For citations where no author is indicated, a superscript number should be placed at the end of the sentence. Respective examples are: "Ma[1] reported", "Pan <i>et al</i> [2-5] indicated"; "PCR has a high sensitivity ^[6,9] ." No superscript numbers are used when the reference number is described in the text; for example, "The experimental method used has been described in reference [8]." The style of reference citations in tables is the same as that in the text (<i>e.g.</i> , Pan <i>et al</i> [2-5], please see reference [8]). Journal references have been verified to ensure that there are no
original articles in accordance with the specified format. The 'REFERENCES' section lists the references in the Vancouver style. This style uses Arabic numeral in-text citations based on the order of the first appearance of a source in the text. For citations where the author's name is indicated in the text, a superscript number should be placed following the name (i.e., "Pang et al"). For citations where no author is indicated, a superscript number should be placed at the end of the sentence. Respective examples are: "Mal ^[1] reported", "Pan et al ^[2-5] indicated"; "PCR has a high sensitivity ^[6,9] ." No superscript numbers are used when the reference number is described in the text; for example, "The experimental method used has been described in reference [8]." The style of reference citations in tables is the same as that in the text (e.g., Pan et al ^[2-5] , please see reference [8]).
style. This style uses Arabic numeral in-text citations based on the order of the first appearance of a source in the text. For citations where the author's name is indicated in the text, a superscript number should be placed following the name (<i>i.e.</i> ., "Pang <i>et al</i> "). For citations where no author is indicated, a superscript number should be placed at the end of the sentence. Respective examples are: "Ma ^[1] reported", "Pan <i>et al</i> ^[2-5] indicated"; "PCR has a high sensitivity ^[6,9] ." No superscript numbers are used when the reference number is described in the text; for example, "The experimental method used has been described in reference [8]." The style of reference citations in tables is the same as that in the text (<i>e.g.</i> , Pan <i>et al</i> ^[2-5] , please see reference [8]).
order of the first appearance of a source in the text. For citations where the author's name is indicated in the text, a superscript number should be placed following the name (<i>i.e.</i> ,, "Pang <i>et al</i> "). For citations where no author is indicated, a superscript number should be placed at the end of the sentence. Respective examples are: "Ma ^[1] reported", "Pan <i>et al</i> ^[2-5] indicated"; "PCR has a high sensitivity ^[6,9] ." No superscript numbers are used when the reference number is described in the text; for example, "The experimental method used has been described in reference [8]." The style of reference citations in tables is the same as that in the text (<i>e.g.</i> , Pan <i>et al</i> ^[2-5] , please see reference [8]).
where the author's name is indicated in the text, a superscript number should be placed following the name (<i>i.e</i> , "Pang <i>et al</i> "). For citations where no author is indicated, a superscript number should be placed at the end of the sentence. Respective examples are: "Ma ^[1] reported", "Pan <i>et al</i> ^[2-5] indicated"; "PCR has a high sensitivity ^[6,9] ." No superscript numbers are used when the reference number is described in the text; for example, "The experimental method used has been described in reference [8]." The style of reference citations in tables is the same as that in the text (<i>e.g.</i> , Pan <i>et al</i> ^[2-5] , please see reference [8]).
number should be placed following the name (<i>i.e.</i> ,, "Pang <i>et al</i> "). For citations where no author is indicated, a superscript number should be placed at the end of the sentence. Respective examples are: "Ma ^[1] reported", "Pan <i>et al</i> ^[2-5] indicated"; "PCR has a high sensitivity ^[6,9] ." No superscript numbers are used when the reference number is described in the text; for example, "The experimental method used has been described in reference [8]." The style of reference citations in tables is the same as that in the text (<i>e.g.</i> , Pan <i>et al</i> ^[2-5] , please see reference [8]).
citations where no author is indicated, a superscript number should be placed at the end of the sentence. Respective examples are: "Ma ^[1] reported", "Pan <i>et al</i> ^[2-5] indicated"; "PCR has a high sensitivity ^[6,9] ." No superscript numbers are used when the reference number is described in the text; for example, "The experimental method used has been described in reference [8]." The style of reference citations in tables is the same as that in the text (<i>e.g.</i> , Pan <i>et al</i> ^[2-5] , please see reference [8]).
be placed at the end of the sentence. Respective examples are: "Ma ^[1] reported", "Pan <i>et al</i> ^[2-5] indicated"; "PCR has a high sensitivity ^[6,9] ." No superscript numbers are used when the reference number is described in the text; for example, "The experimental method used has been described in reference [8]." The style of reference citations in tables is the same as that in the text (<i>e.g.</i> , Pan <i>et al</i> ^[2-5] , please see reference [8]).
reported", "Pan <i>et al</i> ^[2-5] indicated"; "PCR has a high sensitivity ^[6,9] ." No superscript numbers are used when the reference number is described in the text; for example, "The experimental method used has been described in reference [8]." The style of reference citations in tables is the same as that in the text (<i>e.g.</i> , Pan <i>et al</i> ^[2-5] , please see reference [8]).
sensitivity ^[6,9] ." No superscript numbers are used when the reference number is described in the text; for example, "The experimental method used has been described in reference [8]." The style of reference citations in tables is the same as that in the text (e.g., Pan et al ^[2-5] , please see reference [8]).
reference number is described in the text; for example, "The experimental method used has been described in reference [8]." The style of reference citations in tables is the same as that in the text (e.g., Pan et al ^[2-5] , please see reference [8]).
experimental method used has been described in reference [8]." The style of reference citations in tables is the same as that in the text (e.g., Pan et al ^[2-5] , please see reference [8]).
style of reference citations in tables is the same as that in the text (e.g., Pan et $al^{[2-5]}$, please see reference [8]).
(e.g., Pan et al ^[2-5] , please see reference [8]).
Journal references have been varified to encure that there are no
Journal references have been verified to ensure that there are no
duplicate references and that the PMID numbers are correct. For
references not yet included in PubMed: the name of Chinese
journals is spelled out using Chinese Pinyin, with the first letter of
each word capitalized (e.g., Shijie Huaren Xiaohua Zazhi); the name of
journals in other languages are listed according to indexing
information retrieved from Google. Book references are presented
with all the information relevant to the electronic version.
The number of cited references is appropriate for the article type, as
follows:
Commentary: no less than 50;
Review: no less than 100;
Article: no less than 30/26;
Case Report and Letter to the Editor: no less than 1.



-		
	The ethics-related statements are provided in accordance with the	
25	manuscript type (e.g., Manuscript NoInstitutional review board	[Y]
	statement, Manuscript NoAnimal care and use statement, etc.).	
	The names of the peer reviewers and the scientific editor are present	
26	at the end of the paper (e.g., P-Reviewer: Hugot D S-Editor: Wang	[Y]
	JL).	
	The order and numerical labeling of tables and figures is consistent	
	with their appearance and presentation in the text. Symbols in	
	tables (e.g., +, -, \times , \div , *) correctly correspond to the definitions in the	
27	footnotes. Only one legend is provided for each multi-panel figure	7017
27	consisting of color graphs, black and white graphs, or line graphs	[Y]
	that depicts data of the same theme. For example: Figure 1	
	Pathological changes in atrophic gastritis tissue before and after	
	treatment. A:; B:; C:; D:; E:; F:	
28	Split pictures include flow charts, line graphs, histograms, and	[N]
	graphs including text. Unsplit pictures include meta-analysis	
	diagrams, PCR amplification curves, and survival curves.	
20	The author(s) highlighted the changes made to the manuscript	F 2 / 1
29	according to the peer-reviewers' comments.	[Y]
20	The responses to the peer-reviewers' comments are consistent with	F 2 / 1
30	the changes made to the manuscript.	[Y]
31	The revised manuscript is provided (file name: Manuscript	
	NoReview; <i>e.g.</i> , 870- Review).	[Y]
	The letter of peer-reviewers' comments is provided (file name:	
	Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)).	
	The response letter is provided (file name: Manuscript	
	NoAnswering reviewers; e.g., 870-Answering reviewers).	
	The related ethics and relevant documents are provided, such as (1)	
32	Approved grant application form(s) or funding agency copy of any	[Y]
	approval document(s) (file name: Manuscript NoGrant application	



Telephone: +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com

https://www.wjgnet.com

form(s)); (2) Biostatistics review certificate (file name: Manuscript NoBiostatistics statement); (3) Conflict-of-interest statement (file name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form or document (file name: Manuscript NoInstitutional review board statement); (6) Institutional animal care and use committee approval form or document (file name: Manuscript NoInstitutional animal care and use committee statement), and (7) Signed informed consent form(s) or document(s) (file name: Manuscript NoInformed consent statement). All authors signed the BPG Copyright license agreement form (file name: Manuscript NoCopyright license agreement; e.g.,
name: Manuscript NoConflict-of-interest statement); (4) Clinical trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form or document (file name: Manuscript NoInstitutional review board statement); (6) Institutional animal care and use committee approval form or document (file name: Manuscript NoInstitutional animal care and use committee statement), and (7) Signed informed consent form(s) or document(s) (file name: Manuscript NoInformed consent statement). All authors signed the BPG Copyright license agreement form (file
trial registration statement (file name: Manuscript NoClinical trial registration statement); (5) Institutional review board approval form or document (file name: Manuscript NoInstitutional review board statement); (6) Institutional animal care and use committee approval form or document (file name: Manuscript NoInstitutional animal care and use committee statement), and (7) Signed informed consent form(s) or document(s) (file name: Manuscript NoInformed consent statement). All authors signed the BPG Copyright license agreement form (file
registration statement); (5) Institutional review board approval form or document (file name: Manuscript NoInstitutional review board statement); (6) Institutional animal care and use committee approval form or document (file name: Manuscript NoInstitutional animal care and use committee statement), and (7) Signed informed consent form(s) or document(s) (file name: Manuscript NoInformed consent statement). All authors signed the BPG Copyright license agreement form (file
or document (file name: Manuscript NoInstitutional review board statement); (6) Institutional animal care and use committee approval form or document (file name: Manuscript NoInstitutional animal care and use committee statement), and (7) Signed informed consent form(s) or document(s) (file name: Manuscript NoInformed consent statement). All authors signed the BPG Copyright license agreement form (file
statement); (6) Institutional animal care and use committee approval form or document (file name: Manuscript NoInstitutional animal care and use committee statement), and (7) Signed informed consent form(s) or document(s) (file name: Manuscript NoInformed consent statement). All authors signed the BPG Copyright license agreement form (file
approval form or document (file name: Manuscript NoInstitutional animal care and use committee statement), and (7) Signed informed consent form(s) or document(s) (file name: Manuscript NoInformed consent statement). All authors signed the BPG Copyright license agreement form (file
NoInstitutional animal care and use committee statement), and (7) Signed informed consent form(s) or document(s) (file name: Manuscript NoInformed consent statement). All authors signed the BPG Copyright license agreement form (file
Signed informed consent form(s) or document(s) (file name: Manuscript NoInformed consent statement). All authors signed the BPG Copyright license agreement form (file
Manuscript NoInformed consent statement). All authors signed the BPG Copyright license agreement form (file
All authors signed the BPG Copyright license agreement form (file
name: Manuscript No Converight licence agreements as [V]
name: Manuscript NoCopyright license agreement; <i>e.g.</i> , [Y]
870-Copyright license agreement).
The language certificate provided by authors who are non-native
speakers of English meets the BPG requirements (file name: [N]
Manuscript NoLanguage certificate; e.g., 870-Language certificate).
The photos licensed in the Agreement for Use of Personal Photos
are consistent with those in the paper (file name: Manuscript
NoAgreement for use of personal photos; <i>e.g.</i> , 870-Agreement for [N]
use of personal photos).
This document (Checklist of Responsibilities for Scientific Editors)
has been saved under the file name: manuscript NoScientific [Y]
editor work list (e.g., 870-Scientific editor work list).
A CrossCheck investigation (an effective tool for detecting unoriginal
content, enabling our editors to preserve the journal's integrity and
the authors' copyright) has been performed for the manuscript <i>via</i>
the website: http://www.ithenticate.com/. The results document [Y]
contains the following information for the manuscript: "Name of
journal", "Manuscript No.", "Columns", "Title" and "Author list".



Telephone: +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com

https://www.wjgnet.com

	,	1	
	The Figure of the <i>CrossCheck</i> results is saved in JPEG format (.jpg) at		
	1440×680 pixel resolution. The PDF of the <i>CrossCheck</i> results has		
	been saved under the file name: manuscript No CrossCheck report		
	(e.g., 870-CrossCheck report). The Google searches have also been		
	performed to further ensure publication of original content.		
20	The text of the manuscript is typed in Book Antiqua font, 12 pt, with	[2/]	
38	1.5 line spacing.	[Y]	
	The primary responsibilities of our scientific editors include carefully	y checking the	
Responsibilities	entire manuscript and all accompanying materials for: (1) error	s in spelling,	
_	grammar, punctuation and wording; (2) suitability of tables, figures, figure data and		
of scientific legends; (3) accurate and appropriate presentation of symbols (e.g. +, -, ×, ÷, %			
editors	tables and figures; and (4) complete and comprehensive revision of t	he manuscript	
	according to the reviewers' comments.		
	Manuscript reception and registration→Initial review by scientific	editor→Peer	
	review→End of peer review→First round of meeting evalu	ation→To be	
	accepted→Revision by the author(s)→Second round of meeting eval	uation→To be	
	accepted/revised/rejected—Final review by the Editor-in-Chief	(final quality	
Publication	control for academic content and language quality)→Final acceptance	e and charging	
process	of publication fee→Language editing→Production→Proofreading	by scientific	
	editor→Proofreading by deputy editor→Final review by Editor-in-0	Chief→Release	
	of online open-access papers in electronic form on the BPG websi	te→Release of	
	online papers on PubMed Central→Delivery of high-quality PDF 1	reprints to the	
	author(s)→End of the publication process.		